
A lot has happened since Christophe Bourdon was appointed the head of Orphazyme back in early March. In spite of a series of consecutive disappointments, the CEO does not plan to seek other opportunities than the one he currently has as the chief of the Copenhagen-based biotech company, he tells MedWatch.
Following Friday's discouraging announcement that the US Food And Drug Administration (FDA) has given a complete response letter in which it rejects the company's main candidate arimoclomol for treating the metabolic disorder Niemann-Pick type C (NPC)
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app